M. Ibrahim, Zalina Zahari, Nurfadhlina Musa, K. Yin
{"title":"CYP2D6基因多态性:在健康库尔德人中流行","authors":"M. Ibrahim, Zalina Zahari, Nurfadhlina Musa, K. Yin","doi":"10.2174/1875692117666190416145331","DOIUrl":null,"url":null,"abstract":"\n\nIdentifying the genetic polymorphisms of drug metabolizing enzyme\nCYP2D6 is useful in pharmacogenomics. Unfortunately, until today, the prevalence\nof the CYP2D6 polymorphisms among Kurds is scarce.\n\n\n\nIn this study, we explored the CYP2D6 polymorphisms among Kurds.\n\n\n\nFour hundred and fifty-nine unrelated healthy Kurds were recruited for the\nstudy. DNA was extracted from whole blood and was then used for genotyping\nCYP2D6*3, *4, *5, *6, *9, *10, *17, *114 and gene duplication using the nested allelespecific\nmultiplex Polymerase Chain Reaction (PCR).\n\n\n\nThe data add to our knowledge of CYP2D6 alleles, the genotypes and the\ndistributions of predicted phenotypes in Kurds. Majority of the observed variant alleles\nconfer no function and gene duplication. CYP2D6 polymorphisms were found to be very\nheterogeneous in relation to genotype frequencies. Further study in relation to the evaluation\nof drug therapy adjustment based on CYP2D6 genotype may help to understand the\nclinical consequences of CYP2D6 polymorphisms.\n","PeriodicalId":11056,"journal":{"name":"Current Pharmacogenomics and Personalized Medicine","volume":"38 1","pages":"40-47"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Genetic Polymorphisms of CYP2D6: Prevalence in Healthy Kurds\",\"authors\":\"M. Ibrahim, Zalina Zahari, Nurfadhlina Musa, K. Yin\",\"doi\":\"10.2174/1875692117666190416145331\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n\\nIdentifying the genetic polymorphisms of drug metabolizing enzyme\\nCYP2D6 is useful in pharmacogenomics. Unfortunately, until today, the prevalence\\nof the CYP2D6 polymorphisms among Kurds is scarce.\\n\\n\\n\\nIn this study, we explored the CYP2D6 polymorphisms among Kurds.\\n\\n\\n\\nFour hundred and fifty-nine unrelated healthy Kurds were recruited for the\\nstudy. DNA was extracted from whole blood and was then used for genotyping\\nCYP2D6*3, *4, *5, *6, *9, *10, *17, *114 and gene duplication using the nested allelespecific\\nmultiplex Polymerase Chain Reaction (PCR).\\n\\n\\n\\nThe data add to our knowledge of CYP2D6 alleles, the genotypes and the\\ndistributions of predicted phenotypes in Kurds. Majority of the observed variant alleles\\nconfer no function and gene duplication. CYP2D6 polymorphisms were found to be very\\nheterogeneous in relation to genotype frequencies. Further study in relation to the evaluation\\nof drug therapy adjustment based on CYP2D6 genotype may help to understand the\\nclinical consequences of CYP2D6 polymorphisms.\\n\",\"PeriodicalId\":11056,\"journal\":{\"name\":\"Current Pharmacogenomics and Personalized Medicine\",\"volume\":\"38 1\",\"pages\":\"40-47\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-03-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Pharmacogenomics and Personalized Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1875692117666190416145331\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Pharmacogenomics and Personalized Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1875692117666190416145331","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
Genetic Polymorphisms of CYP2D6: Prevalence in Healthy Kurds
Identifying the genetic polymorphisms of drug metabolizing enzyme
CYP2D6 is useful in pharmacogenomics. Unfortunately, until today, the prevalence
of the CYP2D6 polymorphisms among Kurds is scarce.
In this study, we explored the CYP2D6 polymorphisms among Kurds.
Four hundred and fifty-nine unrelated healthy Kurds were recruited for the
study. DNA was extracted from whole blood and was then used for genotyping
CYP2D6*3, *4, *5, *6, *9, *10, *17, *114 and gene duplication using the nested allelespecific
multiplex Polymerase Chain Reaction (PCR).
The data add to our knowledge of CYP2D6 alleles, the genotypes and the
distributions of predicted phenotypes in Kurds. Majority of the observed variant alleles
confer no function and gene duplication. CYP2D6 polymorphisms were found to be very
heterogeneous in relation to genotype frequencies. Further study in relation to the evaluation
of drug therapy adjustment based on CYP2D6 genotype may help to understand the
clinical consequences of CYP2D6 polymorphisms.
期刊介绍:
Current Pharmacogenomics and Personalized Medicine (Formerly ‘Current Pharmacogenomics’) Current Pharmacogenomics and Personalized Medicine (CPPM) is an international peer reviewed biomedical journal that publishes expert reviews, and state of the art analyses on all aspects of pharmacogenomics and personalized medicine under a single cover. The CPPM addresses the complex transdisciplinary challenges and promises emerging from the fusion of knowledge domains in therapeutics and diagnostics (i.e., theragnostics). The journal bears in mind the increasingly globalized nature of health research and services.